NCT06567782 - A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

July 6, 2026

Study Completion Date

June 15, 2028

Conditions

Neoplasms, Colon

Interventions

BIOLOGICAL

Dostarlimab

Dostarlimab will be administered.

DRUG

CAPEOX

CAPEOX chemotherapy consisting of capecitabine and oxaliplatin will be administered.

Trial Locations (12)

1070

RECRUITING

GSK Investigational Site, Brussels

1200

RECRUITING

GSK Investigational Site, Brussels

2820

RECRUITING

GSK Investigational Site, Bonheiden

3000

RECRUITING

GSK Investigational Site, Leuven

4000

RECRUITING

GSK Investigational Site, Liège

8035

RECRUITING

GSK Investigational Site, Barcelona

8400

RECRUITING

GSK Investigational Site, Ostend

8800

RECRUITING

GSK Investigational Site, Roeselare

9000

RECRUITING

GSK Investigational Site, Ghent

9300

RECRUITING

GSK Investigational Site, Aalst

28034

RECRUITING

GSK Investigational Site, Madrid

28222

RECRUITING

GSK Investigational Site, Madrid